Dyne Therapeutics, Inc. - DYN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Mar 06, 2026 | SCHEDULE 13G/A | T. Rowe Price Investment Management, Inc. | 16.2% | 26,578,437 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 8.5% | 13,887,722 | View |
| Jan 08, 2026 | SCHEDULE 13G | T. Rowe Price Investment Management, Inc. | 10.7% | 17,540,089 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 10.4% | 14,745,505 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | RA Capital Management, L.P. | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Peter Kolchinsky | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Rajeev Shah | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 0.0% | 0 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Fund XI, L.P. | 4.0% | 5,697,508 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Associates XI, L.P. | 4.0% | 5,713,470 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Associates XI, LLC | 4.0% | 5,713,470 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Opportunity Fund I, L.P. | 1.0% | 1,458,568 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Associates Opportunity I, L.P. | 1.0% | 1,458,568 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Associates Opportunity I, LLC | 1.0% | 1,458,568 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Opportunity Fund II, L.P. | 1.4% | 1,958,427 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Associates Opportunity II, LP | 1.4% | 1,958,427 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Atlas Venture Associates Opportunity II, LLC | 1.4% | 1,958,427 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.